HANSHOW
September 2022, Hanshow, a professional digital store solution provider (SP), has officially released a whitepaper called “Hanshow Works with Intel and Microsoft to Accelerate Smart Retail Innovation”,written jointly by Hanshow, Intel, and Microsoft. It summarizes changes in the global retail industry and best practices in the retail + AI sector. By examining Hanshow’s partners in China, Japan, and Europe, the whitepaper also illustrates how smart retail technology in the AI era works for global retailers and describes the future development and application trend of AI technology in the retail industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220907005647/en/
Smart store powered by Hanshow (Photo: Business Wire)
AI Technology Innovation Improves Business & Customer Experience
Digitalization is reshaping the global retail industry. Innovative technologies, including AI, computer vision, and the Internet of Things (IoT), are therefore becoming the core tools helping retailers reduce operating costs, improve efficiency, and bring unique shopping experiences to customers. More retailers are using AI technology as a key element to improve business, increase revenue, gain insights into consumer preferences, and optimize store operations.
Liangyan Li SVP, Head of Global Sales, Hanshow, said “Hanshow shall cooperate with leading international companies such as Intel and Microsoft to continuously explore the evolution of AI + retail, unlock the value of data, provide more retailers with better products and solutions, and contribute to the transformation of the global retail market.”
Hanshow Joins Intel and Microsoft to Launch AI Retail Program
Together with Intel and Microsoft, Hanshow therefore has launched AI solutions for the retail industry, focusing on smart shelf management and self-service cashier loss prevention. The use of technology, such as AI cameras and robots, enables retailers to determine the amount of displayed and out-of-stock products with an accuracy of over 95%, by collecting data through commodity identification, and stock inspection. Meanwhile, the edge devices in the scheme solve the problem of sensitive data protection, as well as collect and transmit relevant data for further processing to help businesses find trends and make decisions.
Long-Term Transformative Benefits of AI Solutions for the Retail Industry
The partnership among Hanshow, Intel, and Microsoft in the retail sector has successfully driven the application of AI in the industry. Especially in the post-pandemic period, the digital transformation of the retail industry will help retailers to provide users with a unique and personalized offline service experience to regain their interest and achieve higher business growth.
Guo Wei, General Manager of NEX and Channel DCAI Sales team, PRC Sales Organization, Intel, said " With digital technologies such as AI, virtualization, IoT, and edge computing realizing the upgrade of personalized consumer experiences and the reshaping of innovation-driven retail, the industry is experiencing a lot of changes. ”
Rashmi Misra, General Manager, Microsoft AI & Emerging Technologies, said "AI and IoT are transforming business models by helping companies move from simply making products and services, to companies that give their customers desired outcomes and impeccable experience."
Raj Raguneethan, Regional Business Lead, Retail & Consumer Goods, Microsoft Asia, said “Through the extensive application of AI, retail can become smart, providing better operational excellence, intelligent supply chain, and stronger business intelligence."
About Hanshow
Hanshow is a global leader in developing and manufacturing electronic shelf labels and digital store solutions, offering global customers a series of world-class customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow is used by over 30,000 stores in more than 50 countries, helping retailers streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220907005647/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
